Engineering & Maintenance Senior Manager Utilities

Hovione opens New Jersey facility, doubling U.S. Spray drying capacity. September 16, 2026 Marco Gil, co-CEO Hovione; Janice Mironov, Mayor East Windsor, NJ; Debbie Hart, President BioNJ; Antonio Almeida, co-CEO Hovione; David Basile, VP TechOps Americas Hovione Hovione has opened a new 31,000-square-foot pharmaceutical manufacturing facility at its East Windsor, New Jersey, campus, doubling the contract development and manufacturing organization's U.S. spray drying capacity and completing a $100 million investment cycle in the state. The facility, known as 89 Twin Rivers, adds two GMP-ready, commercial-scale PSD-3 spray dryers to Hovione's U.S. operations. The expansion strengthens the company's ability to move pharmaceutical programs from formulation screening through scale-up and commercial manufacturing of spray-dried amorphous solid dispersions within a single site and quality system. The project also adds approximately 80 jobs and represents the first major milestone in Hovione's longer-term plan to develop East Windsor into a larger pharmaceutical development and manufacturing hub. Spray drying has become an important manufacturing technology for drug developers confronting poor aqueous solubility, which can limit how effectively an active pharmaceutical ingredient is absorbed. Hovione estimates that approximately 70% of small-molecule drug candidates face this problem. The company uses spray drying to produce amorphous solid dispersions that can improve the bioavailability of poorly soluble drug ingredients. Hovione has more than 25 years of experience with the technology, combining formulation science, predictive and model-based development, manufacturing scale-up and finished drug product capabilities. The new capacity sits within a broader integrated platform spanning drug substance, particle engineering and drug product manufacturing. Because 89 Twin Rivers operates under the East Windsor campus' existing FDA registration and harmonized quality system, Hovione said customers can reduce technology transfers as programs advance from development into commercial production. That continuity is increasingly relevant to pharmaceutical companies looking to shorten development timelines and reduce manufacturing risk for complex products. Rather than transferring a formulation among separate development and production sites, Hovione is building capacity to support multiple stages of a program within a common operating environment. "Opening 89 Twin Rivers is more than a capacity expansion," co-CEOs Marco Gil and Antonio Almeida said. "It marks the next chapter in Hovione's legacy of more than two decades in the U.S." They said the investment is intended to meet growing demand for pharmaceutical spray drying while providing customers with a more direct pathway from drug substance through finished drug product. Hovione is already planning another significant expansion in East Windsor. Over the next five to 10 years, the company intends to develop roughly 15 acres of adjacent property with a 125,000-square-foot manufacturing facility. Plans for that site include additional laboratories, commercial-scale spray drying and drug product manufacturing. Hovione also plans to offer customers the ability to co-invest in the expansion in exchange for priority access to its technology platforms, engineering capabilities and accelerated capital deployment for their programs. The strategy positions East Windsor as a larger component of Hovione's international manufacturing network at a time when pharmaceutical companies are placing greater emphasis on regional production capacity and supply-chain resilience. Hovione is pursuing a network of autonomous but harmonized development and manufacturing operations across North America, Europe and Asia. Recent investments in Portugal and Ireland complement the New Jersey expansion and are intended to support regionalized supply and dual-site manufacturing using consistent technologies and quality systems. "89 Twin Rivers is a major step forward for Hovione's U.S. operations and a clear expression of our long-term commitment to East Windsor and New Jersey," said David Basile, vice president of technical operations, Americas. East Windsor Mayor Janice S. Mironov and BioNJ President Debbie Hart joined Hovione executives for a ribbon-cutting ceremony on September 15. Hovione currently works with 19 of the world's 20 largest pharmaceutical companies and says it is involved in as many as 10% of medicines approved annually by the U.S. Food and Drug Administration. The company operates FDA-inspected sites in the U.S., Portugal, Ireland and China, with a fifth site expected to be commissioned in 2027. The East Windsor investment expands Hovione's domestic manufacturing base while reinforcing its strategy of combining specialized formulation technology with development and commercial-scale production, an increasingly important model as drugmakers seek fewer handoffs and more resilient supply options for complex medicines.

Hovione doubles US spray-drying capacity with opening of New NJ facility. This closes a $100 million investment cycle, and creates approximately 80 new jobs. September 16, 2026 Content Marketing Editor Editor's Take: Spray-drying can help create amorphous solid dispersions that turn poorly soluble drug ingredients into more bioavailable forms. Hovione opened a new, 31,000-square-foot facility on Sept. 15, located at 89 Twin Rivers on its East Windsor, NJ campus. Contract Pharma previewed this ribbon-cutting in July, after having gotten to tour Hovione's expanded operations in spring 2026. The new facility adds two commercial-scale PSD-3 spray dryers, both good manufacturing practice (GMP)-ready. As such, it doubles Hovione's United States spray-drying capacity, reinforcing the CDMO's global leadership in this type of technology. Importance of spray-drying. Hovione says approximately 70% of small-molecule drug candidates show poor aqueous solubility. This limits bioavailability and slows development. Amorphous solid dispersions, like those created through Hovione's specialized spray-drying platform, can turn poorly soluble ingredients into more bioavailable forms. Co-CEOs Marco Gil and Antonio Almeida say the expansion is a next chapter after Hovione's two decades-plus in the U.S. "This investment enables us to meet growing demand while further reinforcing our global leadership in pharmaceutical spray drying," they said. "Equally important, this technology sits within an integrated offering that extends from drug substance through drug product. [This gives] customers a more direct and resilient path from early development to commercial. This is how we help them address poor solubility, one of the industry's most persistent development challenges." Hovione committed to NJ. David Basile, Hovione Vice President of Technical Operations, Americas, calls the facility a "clear expression" of a long-term commitment. "Our growth is built on sustained investment in scientific expertise, technological innovation, advanced manufacturing capabilities, and talented people," Basile said. "We will continue to strengthen this site as an innovation hub for pharmaceutical development and manufacturing. [This contributes] to the competitiveness of New Jersey's life sciences ecosystem and to a stronger U.S. manufacturing base." The facility opening completes a $100 million investment cycle, and will employ approximately 80 people. However, Hovione plans to continue growing its U.S. operations, including in East Windsor, over the next decade. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Supplier news: AtomVie, CordenPharma, Hovione, Evonik & more. The latest from CDMOs, CMOs, and suppliers featuring AtomVie, CordenPharma, Northway Biotech, Hovione, Evonik and QPharma. Chemicals/Chemical API Manufacturing AtomVie Radiopharma Opens New $160-M Radiopharmaceutical Mfg Facility AtomVie Global Radiopharma, a CDMO focused on radiopharmaceuticals, has opened a new $160-million manufacturing facility in Hamilton, Ontario, Canada. The 72,300-square-foot facility features low-to-high throughput production and represents more than a tenfold increase in AtomVie's manufacturing capacity. The facility enables progression from early development to commercial manufacturing of radiopharmaceuticals, with customizable space dedicated to clients' future needs. Biologics Manufacturing Northway Biotech Opens $71-M Facility for Cell, Advanced Therapies Northway Biotech, a Vilnius, Lithuania-based CDMO focused on biologics, has opened a EUR 61-million ($71-million) cell therapy and personalized medicine center in Vilnius, Lithuania. The new 3,500-square-meter facility adds development and cGMP manufacturing capacity for advanced and personalized therapies. Northway Biotech's CDMO platform includes mammalian and microbial biologics, gene therapy, and cell-based technologies. Formulation Development/Drug Product Manufacturing CordenPharma Invests $93 M for Sterile Mfg Expansion CordenPharma in making a multi-year EUR 80-million ($93 million) investment for injectable drug products at is site in Caponago (Milan), Italy, with the EUR-13 million ($15 million) acquisition of a new 11,000-square-meter commercial building and 26,000 square meter of land, adjacent to its existing late-stage aseptic fill-finish manufacturing area. This expansion was finalized on July 28, 2026, increasing the site footprint by greater than 50%. The space can accommodate a minimum of four aseptic fill-finish lines, four visual inspection lines, and four additional packaging lines, with options for customer-owned lines, large-scale lyophilization, and auto-injector assembly. Secondly, over the past two years, CordenPharma has embarked on a series of strategic expansions at an existing operational area within its Caponago site that now contributes to the increased injectable capacity by adding two new aseptic fill-finish isolator lines. These include: * A clinical and small-scale commercial combo line from Bausch & Ströbel for prefilled syringes (PFS), vials, and cartridges. * A high-speed PFS and cartridge line from Syntegon, capable of producing >500,000 units per day. * Expansion of the automatic secondary packaging area for PFS, vials, and ampoules. * A doubling of analytical capacity to support growing project pipelines. Completion of the new isolator lines is targeted for mid-2027 and 2028, respectively. Appointments Hovione Names New CEO Hovione has announced the appointment of Stefan Doboczky, currently Chairman of the Board of Directors of Hovione, as Chief Executive Officer (CEO), effective April 1, 2027. Doboczky has served as Chairman of the Board of Directors of Hovione since 2024, where he has been instrumental in shaping the company's strategy and vision. He will step down as Chairman on assuming the role of CEO. The appointment marks a return to the pharmaceutical industry for Doboczky, who spent more than 17 years at Royal DSM, where he became a member of the Executive Board responsible for the group's global pharmaceutical portfolio and for its growth in Asia. He subsequently spent 11 years as CEO of listed, private-equity-owned and corporate-owned industrial companies, including Lenzing AG, Heubach GmbH, and Borealis AG. Following the combination of Borealis, Borouge, and Nova Chemicals into Borouge International, he took on the role of Chief Commercial Officer and Deputy Chairman of the Executive Board of the merged group. He will hand over these responsibilities to his successor on October 1, 2026, and remains available for six months to support the transition. Evonik Names Interim CEO Evonik has appointed Dr. Claus Rettig, currently the Head of Evonik's Asian business, as Interim CEO, taking over for Christian Kullmann, Evonik's current CEO, who is recovering in the upcoming weeks from a recent serious, unplanned surgery. Additionally, Rettig was appointed to Evonik's Executive Board, effective September 1, 2026, and has been appointed Deputy Chairman. Rettig has been with the company for more than 30 years and heads Evonik's Asian business as General Representative in Singapore. Until further notice, Rettig is taking over the duties of Kullmann and will continue his responsibility for Asia as member of the Executive Board. Sever Pharma Solutions Renames to QPharma Sever Pharma Solutions, a Malmö, Sweden-based CDMO specializing in polymer-based complex drug-delivery systems, sterile injectables, and high-potent processing, has changed its name to QPharma AB, effective September 1, 2026.